Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Cited by (1,031)

Items 101–200 of 1,031

1. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
   Hideho Okada, Michael Weller, Raymond Y. Huang, Gaetano Finocchiaro, Mark R. Gilbert, Wolfgang Wick, Benjamin M. Ellingson, Naoya Hashimoto, Ian F. Pollack, Alba Ariela Brandes et al. · 2015 · The Lancet Oncology
2. Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
   Mizuki Nishino, Anita Giobbie‐Hurder, Hiroto Hatabu, Nikhil H. Ramaiya, Frank Stephen Hodi · 2016 · JAMA Oncology
3. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease
   Szabo, Peter A., Levitin, Hanna Mendes, Miron, Michelle, Snyder, Mark E., Senda, Takashi, Yuan, Jinzhou, Cheng, Yim Ling, Bush, Erin C., Dogra, Pranay, Thapa, Puspa et al. · 2019 · Nature Communications
4. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
   Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han, Kongming Wu · 2018 · Molecular Cancer
5. Cutaneous melanoma
   Georgina Venetia Long, Susan M. Swetter, Alexander Maxwell Menzies, Jeffrey E. Gershenwald, Richard A. Scolyer · 2023 · The Lancet
6. Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
   Pedro Henrique de Farias Martins, Joaquim Tiago Cardoso Leles de Jesus, Sofia Nascimento dos Santos, Luís R. Raposo, Catarina Roma‐Rodrigues, Pedro Viana Baptista, Alexandra Ramos Fernandes · 2015 · Molecules
7. The clinical role of the TME in solid cancer
   Nicolás A. Giraldo, Rafael Sánchez-Salas, J. David Peske, Yann Alexandre Vano, Étienne Becht, Florent Petitprez, Pierre Validire, Alexandre Ingels, Xavier Cathelineau, Wolf H. Fridman et al. · 2018 · British Journal of Cancer
8. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
   Frank Stephen Hodi, Wen‐Jen Hwu, Richard F. Kefford, Jeffrey S. Weber, ADIL I. DAUD, Omid Hamid, Amita Patnaik, Antoni Ribas, Caroline Robert, Tara C. Gangadhar et al. · 2016 · Journal of Clinical Oncology
9. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
   Oh, David Y., Kwek, Serena S., Raju, Siddharth S., Li, Tony, McCarthy, Elizabeth, Chow, Eric, Aran, Dvir, Ilano, Arielle, Pai, Chien-Chun Steven, Rancan, Chiara et al. · 2020 · Cell
10. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
    Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B. et al. · 2022 · Journal of Clinical Oncology
11. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
    Hiro Sato, Atsuko Niimi, Takaaki Yasuhara, Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, Mayu Isono, Endang Nuryadi, Ryota Sekine, Takahiro Oike, Sangeeta Kakoti et al. · 2017 · Nature Communications
12. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
    Shona A. Hendry, Roberto Salgado, Thomas Gevaert, Prudence Anne Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen K Van de Vijver, Monica Valeria Estrada, Paula I. González Ericsson et al. · 2017 · Advances in Anatomic Pathology
13. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
    Jonathan Wade Goldman, Mikhail Vladimirovich Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro V. Trukhin, Galina Statsenko, Maximilian Johannes Hochmair, Mustafa Özgüroğlu, Jun Ho Ji et al. · 2020 · The Lancet Oncology
14. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
    Byun, David J., Wolchok, Jedd D., Rosenberg, Lynne M., Girotra, Monica · 2017 · Nature Reviews Endocrinology
15. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
    Padmanee Sharma, Margaret K. Callahan, Petri Bono, Joseph W. Kim, Pavlina Spiliopoulou, Emiliano Calvo, Rathi Narayana Pillai, Patrick Alexander Ott, Filippo de Braud, Michael Andrew Morse et al. · 2016 · The Lancet Oncology
16. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
    Rakesh R. Ramjiawan, Arjan W. Griffioen, Dan Gabriel Duda · 2017 · Angiogenesis
17. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
    Daud, Adil I., Wolchok, Jedd D., Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter et al. · 2016 · Journal of Clinical Oncology
18. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
    McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew et al. · 2018 · The Lancet Oncology
19. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    Gutzmer, Ralf, Stroyakovskiy, Daniil, Gogas, Helen, Robert, Caroline, Lewis, Karl, Protsenko, Svetlana, Pereira, Rodrigo P, Eigentler, Thomas, Rutkowski, Piotr, Demidov, Lev et al. · 2020 · The Lancet
20. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
    Jedd D. Wolchok, Vanna Chiarion‐Sileni, Piotr Lukasz Rutkowski, Charles Lance Cowey, Dirk Schadendorf, John Wagstaff, Paola Queirolo, Reinhard Dummer, Marcus Otho Butler, Andrew G. Hill et al. · 2024 · New England Journal of Medicine
21. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
    Sandra P. D’Angelo, James Larkin, Jeffrey Alan Sosman, Célèste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C. Hassel, Frank Stephen Hodi, Paul C. Lorigan et al. · 2017 · Journal of Clinical Oncology
22. Toxicities of Immunotherapy for the Practitioner
    Jeffrey S. Weber, James Chih‐Hsin Yang, Michael B. Atkins, Mary Lenora Disis · 2015 · Journal of Clinical Oncology
23. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
24. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
25. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    Charlene Marie Fares, Eliezer M. Van Allen, Charles G. Drake, James Patrick Allison, Siwen Hu‐Lieskovan · 2019 · American Society of Clinical Oncology Educational Book
26. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Yongshuai Jiang, Ming Chen, Hong Nie, Yuanyang Yuan · 2019 · Human Vaccines & Immunotherapeutics
27. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
    Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria Isabel Schmidgen, Ralf Gutzmer, Jochen Sven Utikal, Daniela Göppner et al. · 2016 · European Journal of Cancer
28. Cardiovascular Toxic Effects of Targeted Cancer Therapies
    Javid J. Moslehi · 2016 · New England Journal of Medicine
29. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
    Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S. Floudas, Parita Soni, Abhinav Binod Chandra · 2017 · Frontiers in Pharmacology
30. Dermatologic Reactions to Immune Checkpoint Inhibitors
    Vincent Sibaud · 2017 · American Journal of Clinical Dermatology
31. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Olivier Alain Michielin, Alexander C. J. van Akkooi, Paolo A. Ascierto, Reinhard Dummer, Ulrich Keilholz · 2019 · Annals of Oncology
32. Clinical blockade of PD1 and LAG3 — potential mechanisms of action
    Linh T. Nguyen, Pamela S. Ohashi · 2014 · Nature reviews. Immunology
33. Adaptive Immune Resistance: How Cancer Protects from Immune Attack
    Antoni Ribas · 2015 · Cancer Discovery
34. T cell receptor (TCR) signaling in health and disease
    Kinjal Shah, Amr A. Al-Haidari, Jianmin Sun, Julhash Uddin Kazi · 2021 · Signal Transduction and Targeted Therapy
35. Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    Josep Maria Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S. Finn · 2015 · Nature Reviews Clinical Oncology
36. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
    Steve Lu, Julie E. Stein, David L. Rimm, Daphne W. Wang, Michael A. Bell, Douglas Buckner Johnson, Jeffrey Alan Sosman, Kurt Alex Schalper, Robert A. Anders, Hao Wang et al. · 2019 · JAMA Oncology
37. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care
    Emily Zhi-Yun Keung, Jeffrey E. Gershenwald · 2018 · Expert Review of Anticancer Therapy
38. Melanoma
    Dirk Schadendorf, David E. Fisher, Claus Garbe, Jeffrey E. Gershenwald, Jean‐Jacques Grob, Allan C. Halpern, Meenhard Herlyn, Michael Armando Marchetti, Grant A. McArthur, Antoni Ribas et al. · 2015 · Nature Reviews Disease Primers
39. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
    Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saïag, Mark Ross Middleton, Lars Bastholt, Jean‐Jacques Grob, Josep Malvehy, Julia Newton‐Bishop, Alexander Stratigos et al. · 2016 · European Journal of Cancer
40. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
    Bardhan, Kankana, Anagnostou, Theodora, Boussiotis, Vassiliki A. · 2016 · Frontiers in Immunology
41. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
    Grosser, Rachel, Cherkassky, Leonid, Chintala, Navin, Adusumilli, Prasad S. · 2019 · Cancer Cell
42. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
    Hoos, Axel · 2016 · Nature Reviews Drug Discovery
43. The importance of exosomal PDL1 in tumour immune evasion
    Daassi, Dhouha, Mahoney, Kathleen M., Freeman, Gordon J. · 2020 · Nature Reviews Immunology
44. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
    Yearley, Jennifer H., Gibson, Christopher, Yu, Ni, Moon, Christina, Murphy, Erin, Juco, Jonathan, Lunceford, Jared, Cheng, Jonathan, Chow, Laura Q.M., Seiwert, Tanguy Y. et al. · 2017 · Clinical Cancer Research
45. Cutaneous melanoma: From pathogenesis to therapy (Review)
    Giulia Costanza Leonardi, Luca Falzone, Rossella Salemi, Antonio Zanghì, Demetrios A. Spandidos, James Andrew McCubrey, Saverio Candido, Massimo Libra · 2018 · International Journal of Oncology
46. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
    Arce Vargas, Frederick, Furness, Andrew J.S., Litchfield, Kevin, Joshi, Kroopa, Rosenthal, Rachel, Ghorani, Ehsan, Solomon, Isabelle, Lesko, Marta H., Ruef, Nora, Roddie, Claire et al. · 2018 · Cancer Cell
47. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
    Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria et al. · 2016 · Clinical Cancer Research
48. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    Shrujal S. Baxi, Annie W. Yang, Renee L. Gennarelli, Niloufer Khan, Ziwei Wang, Lindsay M. Boyce, Deborah R. Korenstein · 2018 · BMJ
49. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    Kathleen Margaret Mahoney, Gordon James Freeman, David F. McDermott · 2015 · Clinical Therapeutics
50. Resistance to PD1/PDL1 checkpoint inhibition
    Jake S. O’Donnell, Georgina Venetia Long, Richard A. Scolyer, Michele W.L. Teng, Mark John Smyth · 2016 · Cancer Treatment Reviews
51. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
    Jin, Yueping, Dong, Hui, Xia, Liliang, Yang, Yi, Zhu, Yongqiang, Shen, Yan, Zheng, Huajun, Yao, Chengcheng, Wang, Ying, Lu, Shun · 2019 · Journal of Thoracic Oncology
52. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
    Alexander Chan Chi Huang, Roberta Zappasodi · 2022 · Nature Immunology
53. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
    Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., Carpentier, A.F. · 2017 · European Journal of Cancer
54. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
    Douglas Buckner Johnson, Monica Valeria Estrada, Roberto Salgado, Violeta M. Sanchez, Deon Bryant Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate et al. · 2016 · Nature Communications
55. PD-1/PD-L1 inhibitors
    Joel Chaim Sunshine, Janis Marie Taube · 2015 · Current Opinion in Pharmacology
56. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
    Leisha A. Emens, Paolo A. Ascierto, Phillip Kevin Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco Maria Marincola · 2017 · European Journal of Cancer
57. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
    Cheng Xu, Yu‐Pei Chen, Xiao-Jing Du, Jin-Qi Liu, Cheng-Long Huang, Lei Chen, Guan‐Qun Zhou, Wen‐Fei Li, Yan‐Ping Mao, Chiun Hsu et al. · 2018 · BMJ
58. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Xian Shen, Bin Zhao · 2018 · BMJ
59. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation
    Liu, Yuying, Liang, Xiaoyu, Dong, Wenqian, Fang, Yi, Lv, Jiadi, Zhang, Tianzhen, Fiskesund, Roland, Xie, Jing, Liu, Jinyan, Yin, Xiaonan et al. · 2018 · Cancer Cell
60. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
    Rebekka Weber, Viktor Fleming, Xiaoying Hu, Vasyl S. Nagibin, Christopher Groth, Peter Altevogt, Jochen Sven Utikal, Viktor Umansky · 2018 · Frontiers in Immunology
61. Adipocyte and lipid metabolism in cancer drug resistance
    Yihai Cao · 2019 · Journal of Clinical Investigation
62. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
    Routy, Bertrand, Lenehan, John G., Miller, Wilson H., Jamal, Rahima, Messaoudene, Meriem, Daisley, Brendan A., Hes, Cecilia, Al, Kait F., Martinez-Gili, Laura, Punčochář, Michal et al. · 2023 · Nature Medicine
63. Optimizing oncolytic virotherapy in cancer treatment
    Kevin Joseph Harrington, Daniel J. Freeman, Elizabeth J. Kelly, James A. Harper, Jean‐Charles Soria · 2019 · Nature Reviews Drug Discovery
64. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
    Haidong Tang, Yong Liang, Robert A. Anders, Janis Marie Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M. Harrington, Jingya Guo, Yangchun Xin et al. · 2018 · Journal of Clinical Investigation
65. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
    Roberta Zappasodi, Taha Merghoub, Jedd D. Wolchok · 2018 · Cancer Cell
66. Novel patterns of response under immunotherapy
    Édith Borcoman, Yada Kanjanapan, Stéphane Champiat, Shotaro Kato, Vincent Servois, Razelle Kurzrock, Sanjay Goel, Philippe Lucien Bedard, Christophe Le Tourneau · 2019 · Annals of Oncology
67. Roles of regulatory T cells in cancer immunity
    Yoshiko Takeuchi, Hiroyoshi Nishikawa · 2016 · International Immunology
68. The emerging role of resident memory T cells in protective immunity and inflammatory disease
    Chang Ook Park, Thomas Seth Kupper · 2015 · Nature Medicine
69. Advances in targeted therapy for esophageal cancer
    Yuan‐Han Yang, Pan Hong, Wen Wen Xu, Qing‐Yu He, Bin Li · 2020 · Signal Transduction and Targeted Therapy
70. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Adam Mackiewicz, Vanna Chiarion‐Sileni, Ana Maria Arance, Célèste Lebbé, Lars Bastholt, Omid Hamid, Piotr Lukasz Rutkowski et al. · 2017 · The Lancet Oncology
71. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
    Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, Mien‐Chie Hung · 2022 · Nature Reviews Clinical Oncology
72. Targeting the microenvironment in solid tumors
    Carmen Belli, Dario Trapani, Giulia Viale, Paolo D’Amico, Bruno Achutti Duso, Paolo Della Vigna, Franco Orsi, Giuseppe Curigliano · 2018 · Cancer Treatment Reviews
73. Reactive Oxygen Species in the Tumor Microenvironment: An Overview
    Weinberg, Frank, Ramnath, Nithya, Nagrath, Deepak · 2019 · Cancers
74. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
    Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Maria Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Lukasz Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà et al. · 2017 · The Lancet Oncology
75. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
    Capone, Mariaelena, Giannarelli, Diana, Mallardo, Domenico, Madonna, Gabriele, Festino, Lucia, Grimaldi, Antonio Maria, Vanella, Vito, Simeone, Ester, Paone, Miriam, Palmieri, Giuseppe et al. · 2018 · Journal for ImmunoTherapy of Cancer
76. Targeting the gut and tumor microbiota in cancer
    Park, Elizabeth M., Chelvanambi, Manoj, Bhutiani, Neal, Kroemer, Guido, Zitvogel, Laurence, Wargo, Jennifer A. · 2022 · Nature Medicine
77. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
    John A. Thompson, Bryan James Schneider, Julie Renee Brahmer, Stephanie Andrews, Philippe A. Armand, Shailender Bhatia, Lihua Elizabeth Budde, Luciano J. Costa, Marianne J Davies, David Dunnington et al. · 2020 · Journal of the National Comprehensive Cancer Network
78. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review
    Abdel-Wahab, Noha, Shah, Mohsin, Lopez-Olivo, Maria A., Suarez-Almazor, Maria E. · 2018 · Annals of Internal Medicine
79. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio, Vlahovic, Gordana, Lim, Michael, Sahebjam, Solmaz, Baehring, Joachim, Cloughesy, Timothy, Voloschin, Alfredo, Ramkissoon, Shakti H, Ligon, Keith L, Latek, Robert et al. · 2018 · Neuro-Oncology
80. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
    Caroline Robert, Antoni Ribas, Omid Hamid, ADIL I. DAUD, Jedd D. Wolchok, Anthony Michael Joshua, Wen‐Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard Wayne Joseph et al. · 2017 · Journal of Clinical Oncology
81. PD-L1 Expression in Lung Cancer
    Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R. · 2016 · Journal of Thoracic Oncology
82. Immune Checkpoint Inhibitors: Basics and Challenges
    Bin Li, Ho Lam Chan, Pingping Chen · 2017 · Current Medicinal Chemistry
83. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Pengfei Wang, Yang Chen, Siying Song, Tingjian Wang, Wenjun Ji, Shouwei Li, Ning Liu, Changxiang Yan · 2017 · Frontiers in Pharmacology
84. Classification of current anticancer immunotherapies
    Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, Aitziber Buqué, Laura Senovilla, Elisa Elena Baracco, Norma Bloy, Francesca Castoldi, Jean‐Pierre Abastado, Patrizia Agostinis et al. · 2014 · Oncotarget
85. The inflammatory microenvironment and microbiome in prostate cancer development
    Karen Sandell Sfanos, Srinivasan Yegnasubramanian, William G. Nelson, Angelo Michael De Marzo · 2017 · Nature Reviews Urology
86. Synthetic lethality as an engine for cancer drug target discovery
    Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber · 2019 · Nature Reviews Drug Discovery
87. Immunotherapy and Prevention of Pancreatic Cancer
    Alexander H. Morrison, Katelyn T. Byrne, Robert H. Vonderheide · 2018 · Trends in cancer
88. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    Rilan Bai, Zheng Lv, Dongsheng Xu, Jiuwei Cui · 2020 · Biomarker Research
89. Targeting T Cell Co-receptors for Cancer Therapy
    Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2016 · Immunity
90. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
    Tuba Nur Gide, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long · 2017 · Clinical Cancer Research
91. PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
    Aaron Michael Goodman, Sandip Pravin Patel, Razelle Kurzrock · 2016 · Nature Reviews Clinical Oncology
92. Challenges and Opportunities in Cancer Drug Resistance
    Richard A. Ward, Stephen E. Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, Paul D. Smith · 2020 · Chemical Reviews
93. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    Luisa Carbognin, Sara Pilotto, Michèle Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi et al. · 2015 · PLoS ONE
94. Metastatic disease from uveal melanoma: treatment options and future prospects
    Richard D. Carvajal, Gary K. Schwartz, Tongalp H. Tezel, Brian P. Marr, Jasmine H. Francis, Paul Nathan · 2016 · British Journal of Ophthalmology
95. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
    Andrews, Miles C., Duong, Connie P. M., Gopalakrishnan, Vancheswaran, Iebba, Valerio, Chen, Wei-Shen, Derosa, Lisa, Khan, Md Abdul Wadud, Cogdill, Alexandria P., White, Michael G., Wong, Matthew C. et al. · 2021 · Nature Medicine
96. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
    Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher Andrew Barker, William Edgar Carson, Carlo M. Contreras, Gregory A. Daniels, Dominick J. DiMaio, Ryan Courtney Fields, Martin D. Fleming et al. · 2019 · Journal of the National Comprehensive Cancer Network
97. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D. et al. · 2016 · European Journal of Cancer
98. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
    Jeryl Jean Villadolid, Asim Amin · 2015 · PubMed Central
99. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
    Kenji Chamoto, Partha Sarathi Chowdhury, Alok Kumar, Kazuhiro Sonomura, Fumihiko Matsuda, Sidonia Fagarasan, Tasuku Honjo · 2017 · Proceedings of the National Academy of Sciences
100. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
     Delaunay, Myriam, Cadranel, Jacques, Lusque, Amélie, Meyer, Nicolas, Gounant, Valérie, Moro-Sibilot, Denis, Michot, Jean-Marie, Raimbourg, Judith, Girard, Nicolas, Guisier, Florian et al. · 2017 · European Respiratory Journal